Veradermics MANE Balance Sheet Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| $21.77M-59.0% | $53.08M— | ||
| $120.1M— | $0— | ||
| $152.49M+175% | $55.54M— | ||
| $22K— | $0— | ||
| $125K— | $0— | ||
| $152.62M+175% | $55.54M— | ||
| —— | $2.73M— | ||
| $9.15M+94.0% | $4.72M— | ||
| $9.16M+94.1% | $4.72M— | ||
| $1K0.0% | $1K— | ||
| -$123.42M-151% | -$49.23M— | ||
| -$121.01M-150% | -$48.48M-118% | ||
| $152.62M+175% | $55.54M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Veradermics 's total assets?
- Veradermics (MANE) holds $397.4M in total assets.
- How much cash does Veradermics have?
- Veradermics holds $168.4M in cash and equivalents.
- Can Veradermics cover its short-term obligations?
- Its current ratio is 59.12 — current assets exceed current liabilities.
- Where does Veradermics 's balance sheet data come from?
- Every line is extracted from Veradermics 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.